Cholesterol & Cardiovascular Risk Calculator

A total cholesterol of 220 mg/dL with an HDL of 80 (TC/HDL ratio: 2.75) is far healthier than a total of 190 with an HDL of 35 (ratio: 5.4). The ratio captures the balance between atherogenic and protective particles in a single number that predicts cardiovascular risk more reliably than total cholesterol alone. Guidelines now emphasize non-HDL cholesterol — total cholesterol minus HDL — as an even stronger predictor because it captures all plaque-forming particles, including VLDL and intermediate-density lipoprotein (IDL), not just LDL.

The ACC/AHA Pooled Cohort Equations go further by personalizing risk. They incorporate your blood pressure, smoking status, diabetes, and whether you take antihypertensive medication alongside your lipid values, producing a 10-year probability of a major cardiovascular event. Two people with identical LDL can have dramatically different 10-year risks depending on these additional factors. This is why the clinical standard has shifted from treating cholesterol numbers in isolation to treating overall cardiovascular risk — a patient with LDL of 120 and multiple other risk factors may benefit more from a statin than one with LDL of 145 and no other risk factors at all.

HDL is often called the 'good' cholesterol because it performs reverse cholesterol transport — removing LDL from artery walls and delivering it to the liver for elimination. Regular aerobic exercise is the most evidence-based HDL booster, raising levels by 5–10% with consistent training at moderate intensity. The effect is dose-dependent: 150 minutes per week of brisk walking or cycling produces a measurable benefit, and higher volumes improve it further.

Other lifestyle factors also play a role. Replacing saturated fats with monounsaturated fats (olive oil, avocado) improves the LDL-to-HDL ratio by raising HDL while lowering LDL. Quitting smoking raises HDL by approximately 4 mg/dL within weeks of cessation. Modest alcohol consumption (one drink per day for women, two for men) raises HDL by 5–10%, though this benefit is offset by other alcohol-associated health risks at higher volumes. Omega-3 fatty acids from fatty fish or fish oil supplements primarily lower triglycerides (by up to 30% at high doses), which indirectly improves the overall lipid profile. An HDL above 80 mg/dL in the absence of extreme exercise can paradoxically signal certain rare genetic conditions and should be discussed with a physician rather than celebrated uncritically.

Current ACC/AHA guidelines recommend statin therapy in four primary groups: patients with established atherosclerotic cardiovascular disease (ASCVD), patients with LDL of 190 mg/dL or higher (suggesting familial hypercholesterolemia), patients with diabetes aged 40–75, and patients with a 10-year ASCVD risk above 7.5%. Outside these clear indications, a shared decision-making conversation between patient and clinician weighs the magnitude of benefit against potential side effects (most commonly muscle aches, which are usually manageable) and patient preferences.

Lifestyle changes alone can lower LDL by 10–25% — a meaningful reduction for borderline cases but often insufficient for high-risk patients or those with familial hypercholesterolemia. When statins alone cannot achieve target LDL (typically below 70 mg/dL for high-risk patients), ezetimibe — which blocks intestinal cholesterol absorption — can reduce LDL by an additional 15–20%. PCSK9 inhibitors, injectable medications that dramatically upregulate LDL receptor activity, can lower LDL by 50–60% and are reserved for patients at very high risk who cannot reach targets on oral medications alone. The decision about which therapy to use, and at what intensity, is always guided by your overall risk profile rather than any single cholesterol number.